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Suppose they gave a revolution and
nobody came? We’re meant to be in
the midst of a revolution in life
sciences publishing but, for a
revolution, it’s awfully quiet. For the
moment at least, the ancien
régime — in the form of traditional
peer review and conventional
commercial journals — seems to be
winning. The latest fusillade came
from Stanford University’s HighWire
Press, which has just begun offering
free online access to back issues of
dozens of journals.
The revolution was started early
last year by Harold Varmus, then
director of the National Institutes of
Health. Urged on by those who
wanted a freely accessible central
online repository for biology papers
and data, and who were also fed up
with the staggering cost of journals
and the vagaries of peer review,
Varmus threw NIH’s weight behind a
brand new idea. The plan was to
develop a free online ‘e-print’
archive where life scientists could
post papers without having to go
through peer review.
The idea may have been brand
new to biologists but it was modeled
on a highly successful preprint
archive in physics and related fields,
housed at Los Alamos National
Laboratory in New Mexico since
1991. Scientists post draft papers
there, then hunker down to endure
trenchant analysis and the occasional
catcall in the very public peer review
by their fellows.
The Los Alamos e-print archive
seems to work really well — so much
so that it has been expanded to
include papers in mathematics,
computer science, and “non-linear
science”, whatever that is. Papers are
‘published’ with no lag time at all,
revised on the basis of the posted
criticisms, and republished quickly.
By all accounts, the quality of the
papers is good. Perhaps even more
important, the archive is a perpetual
scientific meeting without the jet lag,
a constantly changing, often fruitful
online dialog among members of a
worldwide community of scientists.
In short, it has been good for
scientists and for science.
So, Varmus and his colleagues
reasoned, why not an analagous
e-print archive for biology, free and
open to all? They were quickly told
why not. First, biologists seem to
have faith in peer review. They
concede its imperfections and its
occasional evils, but seem to believe
it is a bulwark against junk science.
(Not to mention much better for
promotion prospects than publishing
unreviewed papers.) Second, a free
archive is a mortal threat to
commercial publishers and to
scientific societies that depend on
journals for income.
Why is a free and open publishing
system bombing with life
scientists?
By last summer, the e-print archive
had become a footnote to the NIH
plan. From then on, the focus was not
only on reviewed papers, it was on
existing journals, and then on back
issues of existing journals. PubMed
Central (its final name) opened its
doors in February containing only
back issues of Molecular Biology of the
Cell. Other journals are said to have
signed up but at this writing none is
available — not even the
much-vaunted catch, Proceedings of the
National Academy of Sciences.
Moreover, on March 1, PubMed
Central was trumped.
HighWire Press, home
site for many journals,
made scores of them
generally  available.
Just three are entirely free;
51 are offering free back issues and
32 are offering free trial access.
HighWire Press now claims to be the
second-largest free full-text science
archive in the world (after Los
Alamos) and, obviously, the largest in
the life sciences.
And what of an e-print archive for
biology? Hanging in there, just. But
not looking healthy. It is a
little-known fact, for example, that
NIH did not entirely abandon its
original supposition that ‘information
wants to be free’. It gave in to those
who declined to be associated with
anything as tacky as unreviewed
e-prints on PubMed Central. But it
has a site, PubMed Express, slated
for just such e-prints. Or it will have
if any life scientists express interest,
says the National Library of
Medicine’s David Lipman. (Lipman
has bravely carried the tattered
banner of publishing revolution since
Varmus relinquished his own stance
at the barricades when he shifted to
the presidency of the
Sloan-Kettering Memorial Cancer
Institute at the end of last year.)
So far, scientists have expressed
no interest whatever in the
still-hypothetical PubMed Express.
Massive lack of excitement has also
attended a couple of other attempts
at establishing a home for
unreviewed papers in the life
sciences, both sponsored by major
UK medical journals.
The Lancet has put up what it
calls an e-print server, but the site’s
content is exclusively papers that
have been or are being considered by
that journal (including a few that
have been rejected). The Lancet
established its electronic research
archive in international health last
summer, to address
neglect of “the
effects of
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electronic publishing on research and
communication in the developing
world.” Doctors there need
affordable access to medical
information, the Lancet said, and
attention should be paid to the
often-forgotten contributions of
researchers there.
After the announcement was
published, the Lancet’s John
McConnell held his breath, awaiting
the flood of submissions. It hasn’t
come. “We’ve had them trickle in,”
he says. “I feared we wouldn’t have
the resources to handle them, but
that has not proved to be true.” At
this writing, the archive contained
just seven papers.
The story is the same at the
British Medical Journal. It launched
Netprints in December as “a place
for authors to archive their
completed studies — before, during,
or after peer review by other
agencies. Its scope is original
research into clinical medicine and
health.” At this writing, Netprints
contained nine papers.
Why is a free and open
publishing system that seems to
work brilliantly in physics and
mathematics bombing with life
scientists? McConnell suggests that
the Lancet’s problem may be lack of
publicity; unless you read the
journal, you probably wouldn’t know
that its international health archive
existed. But he offers that
exculpation with a palpable lack of
conviction. The truth is, he says, that
he’s now more pessimistic than
optimistic about e-publishing.
The European Molecular Biology
Organization (EMBO) is planning
E-Biosci, a journal archive, for late
this year. It will be somewhat similar
to HighWire, offering some free back
issues of journals and links to papers
in current journals that will, in most
cases, require a paid subscription.
Everything on E-Biosci will be
peer-reviewed. Frank Gannon,
EMBO’s executive director, thinks
life scientists are comforted by the
imprimatur of peer review, and for
good reason.
There’s far more possibility of
mischief in biology than in physics,
he says. Unreviewed papers could
send out quasi-scientific messages on
the basis of badly done studies, and
the press might pick them up. An
association with EMBO could confer
respectability on junk science.
Gannon reports that EMBO’s
advisers are also concerned about
politically driven papers — which
might argue, for example, that all
genetically modified organisms are
bad. Another risk is slanted reports
on new products, especially new
drugs. “These things are hard to
work through even with peer
review,” he points out. “We felt it
was wiser to ensure that at least
somebody reads a paper carefully.”
John McConnell concedes that
junk is a risk and that’s why there’s a
preliminary screening process at the
Lancet’s e-print archive. “The quality
of our stuff has been reasonably
good,” he reports. “We haven’t yet
had problems with papers that are
mad, bad, or dangerous.” The BMJ
deals with the junk issue by posting
a stern disclaimer in large type on its
archive’s opening page: “Warning!
Articles posted on this site have not
yet been accepted for publication by
a peer reviewed journal. They are
presented here mainly for the
benefit of fellow researchers. Casual
readers should not act on their
findings, and journalists should be
wary of reporting them.”
Beneath all the palaver about
peer review lurks the mighty iceberg
of the journal-publishing industry.
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Scientific e-publishing ventures have
adopted a confusing tangle of names that
often look and sound alike. Here is a key to
the major players so far.
BioMed Central — A for-profit company in
development, BioMed Central says it will
publish free peer-reviewed e-journals and
post them on PubMed Central and also
offer an unreviewed e-print archive called
BioMed Express. Plans to begin accepting
papers in May. Detailed explanations now
at http://www.biomedcentral.com.
BioMedNet — A for-profit subsidiary of
Reed-Elsevier; provides free news,
networking, and collaborative space for
scientists, plus paid access to journals and
databases. Undergoing redesign at
http://www.biomednet.com/.
COS (Community of Science) — A
for-profit company, COS calls itself “a
network of scientists and research
organizations on the World Wide Web.”
Provides some free services to scientists
and institutions plus paid access to tools for
collaboration and joint authoring, plus some
databases. COS says it plans to serve as a
front end to PubMed Central, but links not
yet available. http://www.cos.com
E-Biomed — Original name for PubMed
Central, no longer in use.
E-Biosci — Europe-based global website
for peer-reviewed scientific literature, a
planned collaboration among publishers,
research organizations, and EMBO. Hopes
to begin this year. No URL yet.
HighWire Press — The home site for many
peer-reviewed journals has just made
scores of them publicly available. Only
three are entirely free; 51 are offering free
back issues and 32 are offering free trial
access. Claims to be the second-largest
free full-text science archive in the world
and the largest in the life sciences.
http://highwire.stanford.edu/lists/freeart.dtl
The Lancet — An electronic research
archive for unreviewed e-prints in
international health. Free.
http://www.thelancet.com/newlancet/eprint
Netprints — Set up by the British Medical
Journal as a place for authors to archive
their completed studies — before, during, or
after peer review. Free.
http://clinmed.netprints.org
PubMed — Free search tool for accessing
literature citations and linking to full-text
journals at web sites of participating
publishers. Developed by the National
Center for Biotechnology Information
(NCBI), part of the National Library of
Medicine at NIH. Recently added short
reviews and consumer health information
to the site.
http://www.ncbi.nlm.nih.gov/PubMed/
PubMed Central — Free NIH repository for
peer-reviewed primary research reports in
the life sciences, originally called
E-Biomed. At present plans to post back
issues of a few journals.
http://www.pubmedcentral.nih.gov/
PubMed Express — Future free NIH
repository for e-prints, research reports
that have not (or not yet) been
peer-reviewed. URL will be
http://www.pubmedexpress.nih.gov.
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Commercial publishers (such as
Elsevier Science, which owns Current
Biology, and the Lancet) are large and
profitable — unhappy librarians say
outrageously profitable — and
understandably not delighted at the
thought of competitors that are
universally accessible and free. Many
scientific societies believe they
would perish if people fancied free
e-prints instead of their journals,
which serve as magnets — often the
only magnets — for members and
income. They may be right.
There’s far more possibility of
mischief in biology than in physics
Gannon, for one, says he is more
worried about the survival of
scientific societies than of
commercial publishers, although
many of the latter are advising
EMBO’s project. We’ve ended up
with the present system of
commercial publishers because they
do it efficiently — and because
capitalism rules, he argues. But he
hopes an increasing amount of
material will be offered free as the
societies — and perhaps commercial
publishers as well — become
comfortable with reducing the
amount of delay between an issue’s
publication date and the time it
becomes available gratis.
John McConnell points out that it
is really too early to say whether
unreviewed e-prints will ever catch
on in the life sciences. The concept
may become more acceptable, he
says, as people learn about it and do
it, and if some sponsor is willing to
hang in there for a long time waiting
for it to work. It is clear he is no
longer holding his breath.
For now at least, events on the
barricades of the life sciences
publishing revolution suggest that the
Jacobins have yet to make their mark.
Tabitha M. Powledge is a freelance writer and
editor who specializes in genetics,
neuroscience and science policy.
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The Cancer Research
Campaign
What is it famous for? The Cancer
Research Campaign (CRC) is one of
two rival charities that dominate
cancer research funding in the UK
— the other being the Imperial
Cancer Research Fund (ICRF). But
most British people are probably
more aware of the CRC’s charity
shops, which are on almost every
high street.
How did it begin? In 1923, a group of
clinicians, who felt that the work of
the ICRF had reached a “dried up
condition of stagnation”, founded
the British Empire Cancer Campaign
for Research, the forerunner to the
CRC. According to Sir Walter Morley
Fletcher — who, in his capacity as
first secretary of the Medical
Research Council, co-ordinated all
British medical research at the
time — the founders of the CRC
showed “almost avowed rivalry, not
untinged by hostility” to the ICRF.
This rivalry continues to this day,
albeit less overtly.
Does it have much money to give away?
The CRC spent £56 million
(US$89 million) on research in 1999.
Compare this with the £23 million
spent by the UK government on
cancer research last year.
Where does the money come from?
About 87% of its £69 million income
in 1999 came from legacies and
donations. The CRC’s chain of
charity shops raised £4 million. The
charity has also become more
inventive with its fundraising in the
past couple of years. Through a
partnership with the International
Star Registry, anyone can name a
star in the constellation of Cancer,
in return for a small contribution to
the CRC. The charity has also
entered into endorsement
partnerships with the likes of
Kellogg’s, the breakfast cereal
makers. It remains to be seen
whether the amount of effort
devoted by the CRC to getting
publicity for the partnerships will be
justified by the returns.
Where is it based? The charity’s
fundraising and media relations
machinery, and its grant
administrators, are based in its
headquarters in central London.
The CRC’s one-stop cancer
information service — staffed by
biomedical professionals — is also
based there.
What’s it like to work there? Well,
whether or not it makes a difference
to the atmosphere there, men are
very much in the minority. Although
the present Director General of the
CRC (Gordon McVie) is male,
women make up 88% of the 825 staff
at headquarters. TV crews and
reporters seem to be ever-present,
eager for the scoop on the next
cancer ‘breakthrough’, and there’s
usually a pleasant bustle of activity
— but this shifts up several gears
whenever the ICRF receives one
column inch of publicity more than
the CRC.
Does the CRC have its own labs? No.
Unlike the ICRF, which directly
employs scientists at its own labs, the
CRC provides funding purely
through research grants, although it
does also provide personal support in
the form of fellowships and
studentships. This allows it the
flexibility to support scientists no
matter where they are based (within
the UK), and it avoids expensive
overheads for bricks and mortar.
Has it funded any well-known work?
Yes. David Lane, co-discoverer of the
p53 tumour suppressor, and Mike
Stratton, whose team identified and
cloned the breast cancer susceptibility
gene BRCA2, are two of the 1,300
scientists funded by the CRC.
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